The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus

BACKGROUND: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the v...

Descripción completa

Detalles Bibliográficos
Autores principales: Maldonado, M.D., Romero-Aibar, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556178/
https://www.ncbi.nlm.nih.gov/pubmed/34746880
http://dx.doi.org/10.1016/j.bbih.2021.100381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556178/
https://www.ncbi.nlm.nih.gov/pubmed/34746880
http://dx.doi.org/10.1016/j.bbih.2021.100381

Ejemplares similares